FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and refers to the dosage regimen of a phosphatidylinositol-3-kinase inhibitor (PI3K) in cancer treatment. 5-(2,6-dimorpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethylpyridin-2-ylamine or a pharmaceutically acceptable salt thereof in a therapeutically effective amount of approx. 60 to approx. 120 mg per day, for five consecutive days in any seven-day period is used as the phosphatidylinositol-3-kinase inhibitor.
EFFECT: reduced side effects of the therapy.
9 cl, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IDENTIFICATION OF LKB1 MUTATION AS PROGNOSTIC BIOMARKER OF SENSITIVITY TO TOR-KINASE INHIBITORS | 2011 |
|
RU2565034C2 |
| PHARMACEUTICAL COMBINATION COMPRISING INHIBITOR PHOSPHATYLENOSITOL 3-KINASES AND AROMATASE INHIBITOR | 2013 |
|
RU2651023C2 |
| USE OF 2-CARBOXAMIDE-CYCLOAMINO UREA DERIVATIVES IN TREATMENT OF EGFR-DEPENDENT DISEASES OR DISEASES WITH ACQUIRED RESISTANCE TO AGENTS TARGETED AT EGFR-FAMILY MEMBERS | 2011 |
|
RU2589695C2 |
| COMPOUNDS WHICH ARE ERK INHIBITORS | 2009 |
|
RU2525389C2 |
| THERAPEUTIC COMPOUNDS AND COMPOSITIONS AND METHODS OF USING THEM | 2018 |
|
RU2769696C2 |
| METHOD FOR TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS | 2017 |
|
RU2765737C2 |
| COMBINATION, INCLUDING A) PYRIMIDYLAMINOBENZAMIDE AND B) KINASE Thr315lle INHIBITOR | 2007 |
|
RU2481840C2 |
| 2-CARBOXAMIDE CYCLOAMINO UREA DERIVATIVES IN COMBINATION WITH HSP90 INHIBITORS FOR TREATING PROLIFERATIVE DISEASES | 2012 |
|
RU2624493C2 |
| COMBINATION OF PYRIMIDYLAMINOBENZAMIDE AND mTOR KINASE INHIBITOR | 2006 |
|
RU2443418C2 |
| CERTAIN PROTEIN KINASE INHIBITORS | 2017 |
|
RU2738837C2 |
